Skip to main content

DOACs in Renally Impaired Patients

  • Atrial fibrillation is common in patients with CKD, with rates significantly higher than in the general population. CKD significantly increases thromboembolic risk above baseline and is also associated with increased risk of bleeding. The evidence to support oral anticoagulants (vitamin K antagonist or direct oral anticoagulants [DOACs]) is less robust in individuals with reduced creatinine clearance. The use of direct oral anticoagulants does represent an important opportunity and challenge in patients with impaired kidney function. This presentation by Dr. Jason Andrade reviews the literature on DOAC use with a specific focus on Edoxaban in chronic kidney disease.
  • Jason Andrade, M.D., FRCPC, FHRS, is a Cardiac Electrophysiologist at Vancouver General Hospital in Canada, with joint appointment at the Montreal Heart Institute. He is an Associate Professor of Medicine at the University of British Columbia (UBC), and an Assistant Professor at the Université de Montréal.

    See Dr. Andrade's full bio here.

  • Dr. Andrade created the slide content appearing in this presentation. He was provided an honorarium by Servier Canada to support the time spent on preparing and delivering this presentation.